Sumit K. Shah
Research Assistant
Also affiliated: Stevens Institute of Technology (1999); Northwestern University (2024); University of California, Los Angeles (2004–2011); University of Arkansas Medical Center (2019); Indus Hospital (2011); Muhlenberg Regional Medical Center (1999); St. Francis Hospital (2018); Texas Cardiac Arrhythmia (2018)
Graduate Student Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Sumit K. Shah's research focuses on public health, with a significant emphasis on understanding and addressing disparities in health outcomes and access to care. His work has investigated factors influencing vaccine hesitancy and uptake, particularly in relation to COVID-19, and has explored the experiences of discrimination among various demographic groups in the context of vaccination.
Shah's publications also address screening disparities for conditions such as colorectal and breast cancer, applying health behavior models to analyze service use among men and women in the United States. He has collaborated with researchers at the University of Arkansas for Medical Sciences and the University of Arkansas at Fayetteville, contributing to a body of work that includes 62 publications and over 1,230 citations, with an h-index of 20.
His research group's activities and publications demonstrate a commitment to examining sociodemographic determinants of health behaviors and disparities, with recent work extending to parent/guardian intentions for child vaccination and factors associated with cancer screening service use. Shah is recognized as a highly cited researcher.
Metrics
- h-index: 21
- Publications: 62
- Citations: 1,240
Selected Publications
-
Correction: Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans (2025)
-
Corrigendum to “COVID-19 vaccine hesitancy and racial discrimination among US adults” [Pre. Med. Rep. 31 (2022) 102074] (2025)
-
Acute Myeloid Leukemia with Hemophagocytosis: Diagnostic Cues and Potential Pitfalls. (2025)PubMed OpenAlex
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Evusheld, a SARS-CoV-2 spike protein–directed attachment inhibitor, appears in serum protein electrophoresis and immunofixation: a case study (2023)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Factors associated with breast cancer screening services use among women in the United States: An application of the Andersen's Behavioral Model of Health Services Use (2023)
-
Comparing community-driven COVID-19 vaccine distribution methods: Faith-based organizations vs. outpatient clinics (2022)
-
COVID-19 vaccine hesitancy and racial discrimination among US adults (2022)
-
Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans (2022)
-
Assessment of Colorectal Cancer Screening Disparities in U.S. Men and Women Using a Demographically Representative Sample (2022)
-
Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans (2022)
-
Parent/guardian intentions to vaccinate children against COVID-19 in the United States (2022)
-
COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults (2022)
-
Parents’ and Guardians’ Intentions to Vaccinate Children against COVID-19 (2022)
Collaboration Network
Top Collaborators
- Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy
- COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults
- COVID-19 vaccine hesitancy and racial discrimination among US adults
- “The Risk Seems Too High”: Thoughts and Feelings about COVID-19 Vaccination
- Parent/guardian intentions to vaccinate children against COVID-19 in the United States
Showing 5 of 16 shared publications
- Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy
- COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults
- COVID-19 vaccine hesitancy and racial discrimination among US adults
- “The Risk Seems Too High”: Thoughts and Feelings about COVID-19 Vaccination
- Parent/guardian intentions to vaccinate children against COVID-19 in the United States
Showing 5 of 10 shared publications
- Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy
- COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults
- COVID-19 vaccine hesitancy and racial discrimination among US adults
- Parent/guardian intentions to vaccinate children against COVID-19 in the United States
- Parents’ and Guardians’ Intentions to Vaccinate Children against COVID-19
Showing 5 of 10 shared publications
- COVID-19 vaccine hesitancy and racial discrimination among US adults
- Parent/guardian intentions to vaccinate children against COVID-19 in the United States
- Parents’ and Guardians’ Intentions to Vaccinate Children against COVID-19
- Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans
Showing 5 of 8 shared publications
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures
- COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults
- COVID-19 vaccine hesitancy and racial discrimination among US adults
- Parent/guardian intentions to vaccinate children against COVID-19 in the United States
- Parents’ and Guardians’ Intentions to Vaccinate Children against COVID-19
- Corrigendum to “COVID-19 vaccine hesitancy and racial discrimination among US adults” [Pre. Med. Rep. 31 (2022) 102074]
- COVID-19 Vaccine Hesitancy and Experiences of Discrimination Among Black Adults
- Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans
- Correction: Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans
- Comparing community-driven COVID-19 vaccine distribution methods: Faith-based organizations vs. outpatient clinics
- Correction: Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans
- Comparing community-driven COVID-19 vaccine distribution methods: Faith-based organizations vs. outpatient clinics
- Correction: Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans
- Comparing community-driven COVID-19 vaccine distribution methods: Faith-based organizations vs. outpatient clinics
- Correction: Associations Between General Vaccine Hesitancy and Healthcare Access Among Arkansans
- An Online Survey and Focus Groups for Promoting Cancer Prevention Measures
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Similar Researchers
Based on overlapping research topics